NCT06094725View on ClinicalTrials.gov

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 6, 2020

Primary Completion Date

December 14, 2020

Study Completion Date

December 14, 2020

Conditions
Hepatic Impairment
Interventions
DRUG

Relacorilant

Relacorilant 300 mg (3 X 100 mg softgel capsules) for oral administration

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, LLC, Miami

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY